# Trends on Strategies for Mitigation of Antibiotic Residues in Milk and Dairy Products Based on Scientometric Analysis and Systematic Review

**Authors:** Emelda Orlando Simbine‐Ribisse, Wilma Custódio Fumo, Eugénio da Piedade Edmundo Sitoe, Patrícia Aparecida de Campos Braga, Cristiano João Macuamule, Adriana Pavesi Arisseto Bragotto

PMC · DOI: 10.1111/1541-4337.70398 · Comprehensive Reviews in Food Science and Food Safety · 2026-01-16

## TL;DR

This study reviews research trends on reducing antibiotic residues in milk and dairy products, highlighting the shift toward nonthermal technologies.

## Contribution

The paper combines scientometric and systematic review methods to identify emerging mitigation strategies and research gaps.

## Key findings

- Heat treatment is the most studied mitigation strategy for antibiotic residues in milk.
- Nonthermal technologies like pulsed electric field and ozonation are gaining attention for preserving milk quality.
- No single mitigation strategy is universally effective, suggesting the need for combined approaches.

## Abstract

The presence of antibiotic residues (ARs) in milk poses a significant challenge to public health and the dairy industry. This study presents the research trends on strategies to mitigate ARs in milk and dairy products, combining scientometric and systematic review approaches. Following the PRISMA guidelines, data from Web of Science, ScienceDirect, PubMed, Embase, AGRICOLA, and CAS Abstract yielded 49 original articles. Geographical analysis revealed a heterogeneous distribution, with Spain as the leading contributor. The analysis showed that heat treatment is the most studied mitigation strategy, reflecting its widespread industrial implementation. Crucially, a clear trend indicates the growth of emerging nonthermal technologies, such as pulsed electric field (PEF) and ozonation, driven by the need to preserve the nutritional and sensory attributes of milk. The most studied antibiotics belong to the tetracycline and penicillin classes, with oxytetracycline being most frequently investigated, followed by penicillin, tetracycline, ampicillin, chlortetracycline, cloxacillin, and amoxicillin. The findings confirm that no single strategy is universally effective. The results indicate that the future of ARs mitigation lies in the development of synergistic and combined approaches to achieve industrially viable, cost‐effective protocols that preserve product quality. This study highlights the need for future research focused on selective technologies and the assessment of by‐product toxicity, alongside the regulatory aspects for the application of these technologies.

## Linked entities

- **Chemicals:** oxytetracycline (PubChem CID 54675779), penicillin (PubChem CID 2349), tetracycline (PubChem CID 54675776), ampicillin (PubChem CID 6249), chlortetracycline (PubChem CID 54675777), cloxacillin (PubChem CID 6098), amoxicillin (PubChem CID 33613)

## Full-text entities

- **Genes:** BCAR1 (BCAR1 scaffold protein, Cas family member) [NCBI Gene 9564] {aka CAS, CAS1, CASS1, CRKAS, P130Cas}
- **Diseases:** toxicity (MESH:D064420)
- **Chemicals:** ampicillin (MESH:D000667), chlortetracycline (MESH:D002751), amoxicillin (MESH:D000658), tetracycline (MESH:D013752), penicillin (MESH:D010406), cloxacillin (MESH:D003023), oxytetracycline (MESH:D010118)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12809382/full.md

## Figures

15 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12809382/full.md

## References

134 references — full list in the complete paper: https://tomesphere.com/paper/PMC12809382/full.md

---
Source: https://tomesphere.com/paper/PMC12809382